Bioptik Technology, Inc. (4161) AI Stock Analysis

Bioptik Technology, Inc.

(TPEx:4161)

Select Model

Rating:61Neutral

Price Target:TWD 22.00▲(5.52% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by weak cash generation, declining margins, and negative technical momentum. A relatively strong balance sheet, continued profitability, and attractive valuation provide meaningful support.

Positive Factors

Improved Balance SheetLower leverage and a larger equity base indicate meaningful balance-sheet de-risking. This should improve financial flexibility, reduce sensitivity to financing stress, and give the company a stronger foundation for sustaining operations or funding future growth.

Negative Factors

Sharp Cash Flow DeteriorationThe steep 2025 decline in operating and free cash flow weakens internal funding capacity and makes earnings less dependable as a source of liquidity. Lower cash conversion can constrain investment, dividends, and debt reduction while increasing exposure to future cash-flow volatility.

Bioptik Technology, Inc. (4161) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.24B
Dividend Yield: 3.36%
Average Volume (3M): 24.43K
Price to Earnings (P/E): 11.2
Beta (1Y): 0.19
Revenue Growth: 7.54%
EPS Growth: 35.87%
Country: TW
Employees: 80
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Bioptik Technology, Inc. Business Overview & Revenue Model

Company Description

Bioptik Technology Incorporation operates as a global entity, focusing on the creation and distribution of medical instruments and diagnostic chemicals. The company's product line encompasses the EasyMate series of blood glucose monitoring systems, a...

Bioptik Technology, Inc. Financial Statement Overview

Summary

Profitability remains positive and the balance sheet is relatively strong, with improved leverage and growing equity. However, declining margins and sharply weaker operating and free cash flow materially reduce financial quality.

Income Statement

68Positive

Balance Sheet

78Positive

Cash Flow

42Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	912.86M	837.19M	865.34M	828.50M	767.75M	737.89M
Gross Profit	257.09M	243.51M	267.90M	239.54M	177.46M	163.54M
EBITDA	119.07M	99.50M	155.10M	152.18M	105.47M	64.41M
Net Income	108.09M	71.19M	93.57M	85.71M	48.50M	22.59M
Balance Sheet
Total Assets	1.62B	1.57B	1.49B	1.50B	1.52B	1.52B
Cash, Cash Equivalents and Short-Term Investments	442.58M	448.38M	422.29M	394.13M	332.61M	344.85M
Total Debt	467.82M	470.47M	451.02M	523.24M	662.87M	685.91M
Total Liabilities	630.28M	597.14M	582.47M	673.56M	797.40M	829.38M
Stockholders Equity	988.38M	969.36M	901.27M	819.34M	715.13M	690.25M
Cash Flow
Free Cash Flow	32.90M	24.66M	143.32M	174.91M	37.98M	-60.97M
Operating Cash Flow	51.05M	43.83M	158.82M	205.95M	55.06M	-41.15M
Investing Cash Flow	-32.43M	-34.03M	-12.44M	-28.53M	187.14M	-118.61M
Financing Cash Flow	26.39M	-964.00K	-134.36M	-119.33M	-35.56M	5.65M

Bioptik Technology, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4161 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4161	61Neutral	TWD 1.22B	11.21	―	3.36%	7.54%	35.87%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4133	48Neutral	TWD 1.20B	26.82	―	0.56%	-4.19%	―
TW:4109	45Neutral	TWD 1.21B	255.00	―	1.96%	13.00%	902.22%

* General Sector Average

Performance Comparison

TW:4161 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4161	Bioptik Technology, Inc.	20.85	-4.80	-18.71%
TW:4109	Jia Jie Biomedical Co., Ltd.	10.20	-5.51	-35.08%
TW:4133	Abnova Taiwan Corp.	19.85	-3.42	-14.71%
TW:4195	Genomics BioSci & Tech. Co., Ltd.	14.85	-9.75	-39.63%
TW:6857	Acer Medical Inc.	89.00	-29.50	-24.89%
TW:7530	Forward Science Corp.	28.45	14.63	105.88%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Bioptik Technology, Inc. AI Stock Analysis